In vitro and in vivo pharmacology and pharmacokinetics of a human engineered™ monoclonal antibody to epithelial cell adhesion molecule

Neoplasia

Volumn 5, Issue 2, 2003, Pages 146-154

  Ammons, W Steve ^a   Bauer, Robert J ^a   Horwitz, Arnold H ^a   Chen, Zhi J ^a   Bautista, Eddie ^a   Ruan, Harry H ^a   Abramova, Marina ^a   Scott, Kristen R ^a   Dedrick, Russell L ^a  

^a XOMA Corporation   (United States)

Author keywords

ADCC; Anti Ep CAM; ING 1; Pharmacokinetics; Xenograft

Indexed keywords

CELL ADHESION MOLECULE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ING 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ENGINEERING; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT; TUMOR XENOGRAFT;

EID: 0037348332     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(03)80006-4     Document Type: Article

References (51)

1. Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, Carrano R, and LoBuglio AF (1998). Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A: II. Pharmacokinetics and immune response. J Natl Cancer Inst 80, 937-42.
2. Shawler DL, Bartholomew RM, Smith LM, and Dillman RO (1985). Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135, 1530-35.
3. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Grayeb J, and Khazaeli MB (1989). Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86, 4220-24.
4. Weiden PL, Breitz HB, Seiler CA, Bjorn MJ, Ratliff BA, Mallett R, Beaumier PL, Appelbaum JW, Fritzberg AR, and Salk D (1993). Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10. J Nucl Med 34, 2111-19.
5. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, and Woody JN (1994). Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344, 1105-10.
6. 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 15, 5461-66.
7. Graves SS, Goshorn SC, Stone DM, Axworthy DB, Reno JM, Bottino B, Searle S, Henry A, Pedersen J, Rees AR, and Libby RT (1999). Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody. Clin Cancer Res 5, 899-908.
8. Huls GA, Heijnen IA, Cuomo ME, Koningsberger JC, Wiegman L, Boel E, van der uurst de Vries AR, Loyson SA, Helfrich W, van Berge Henegouwen G, van Meijer M, de Kruif J, and Logtenberg T (1999). A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 17, 276-81.
9. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmuller G, Baeuerle PA, and Dreier T (2002). In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100, 101-10.
10. Jones PT, Dear PH, Foote J, Neuberger MS, and Winter G (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-25.
11. Herlyn M, Steplewski Z, Herlyn D, and Koprowski H (1979). Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76, 1438-46.
12. Perez MS, and Walker LE (1989). Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker. J Hematol 142, 3662-67.
13. Strnad J, Hamilton AE, Beavers LS, Gamboa GC, Apelgren LD, Taber LD, Sportsman JR, Bumol TF, Sharp JD, and Gadski RA (1989). Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementarity DNA. Cancer Res 49, 314-17.
14. Simon B, Podolsky DK, Moldenhauer G, Isselbacher KJ, Gattoni-Celli S, and Brand SJ (1990). Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein. Proc Natl Acad Sci USA 87, 2755-59.
15. Szala S, Froehlich M, Scollon M, Kasai Y, Steplewski Z, Koprowski H, and Linnenbach AJ (1990). Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci 87, 3542-46.
16. Balzar M, Winter MJ, deBoer CJ, and Litvinov SV (1999). The biology of the 17-1A antigen (Ep-CAM). J Mol Med 77, 699-712.
17. Shaw DR, Khazaeli MB, Lee KS, Ghrayeb J, Daddona PE, McKinney S, and LoBuglio AF (1987), Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. J Immunol 138, 4534-38.
18. Herlyn D, and Koprowski H (1982). IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci 79, 4761-65.
19. Masucci G, Lindemalm C, Frodin J-E, Hagstrom B, and Mellstedt H (1988). Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and BR55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948). Hybridoma 7, 429-40.
20. Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, and Koprowski H (1988). Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci 85, 4852-56.
21. Velders MP, Litvinov SV, Warnaar SO, Gorter A, Fleuren GJ, Zurawski VR Jr, and Coney LR (1994). New chimeric anti-pancarcinoma monoclonal antibody and superior cytotoxicity-mediating potency. Cancer Res 54, 1753-59.
22. Velders MP, vanRhijn CM, Briaire IH, Fleuren GJ, Warnaar SO, and Litvinov SV (1995). Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. Cancer Res 55, 4398-403.
23. Velders MP, vanRhijn CM, Cornelissen IM, van Muijen GN, Briaire I, Hohlsten M, Fleuren GJ, Warnaar SO, and Litvinov SV (1996). The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease. J Immunother 19, 245-56.
24. Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, and Litvinov SV (1998). The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br J Cancer 78, 478-83.
25. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmmaier H, Hierche H, Pichlmayr R, Buggisch P, and Witte J (1994). Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343, 1177-83.
26. Saleh MN, Posey JA, Khazaeli MB, Thurmond M, Khor SP, Lampkin TA, Wissel PS, and LoBuglio AF (1998). Phase I trial testing multiple doses of humanized monoclonal antibody (MAB) 3622W94. Proc ASCO 17, 436a.
27. Liao S-K, Horton L, Flahart RE, O'Rear L, Crumpacker D, Imbaratto JW, Yannelli JR, Robinson RR, and Oldham RK (1990). Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas. Hum Antib Hybridomas 1, 66-76.
28. Kufe DW, Nadler L, Sargent L, Shapiro H, Hand P, Austin F, Colcher D, and Schlom J (1983). Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res 43, 851-57.
29. Robinson RR, Chartier J, Chang CP, Horwitz AH, and Better M (1991). Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities. Hum Antib Hybridomas 2, 84-93.
30. Studnicka GM, Scares S, Better M, Williams RE, Nadell R, and Horwitz R (1994). Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-complementarity-modulating residues. Protein Eng 17, 805-14.
31. de Bono JS, Forero A, Hammond LA, Patnaik A, Takimoto C, Lobuglio A, Mays T, Rowinsky EK, Bauer R, Van Hove G, and Tolcher A (2002). Safety, tolerability, and maximum tolerated dose of an intravenously administered human engineered monoclonal antibody, ING-1(he-MAb), in patients with advanced adenocarcinomas. Proc ASCO 21, 9a.
32. Better M, Bohmann KJ, White ML, Forero A, de Bono JS, Hamond LA, Patnaik A, Takimoto C, LoBuglio A, Rowinsky EK, Tolcher AW, and Vanhove GF (2002). Recombinant human engineered ING-1 monoclonal antibody, ING-1(heMAb), exhibits minimal immunogenicity in patients with advanced adenocarcinomas. Proc ASCO 21, 20a.
33. Gibaldi N, and Perrier D (1982). Multicompartment models. In Pharmacokinetics (2nd ed). Marcel Dekker, New York, pp. 45-111.
34. 125I-antibody therapy efficacy in multicell spheroids. Cancer Res 52, 4728-34.
35. Sung C, Shockley TR, Morrison PF, Dvorak HF, Yarmush ML, and Dedrick RL (1992). Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res 52, 377-84.
36. Shockley TR, Lin K, Sung C, Nagy JA, Tompkins RG, Dedrick RL, Dvorak HF, and Yarmush ML (1992). A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 52, 357-66.
37. Kievit E, Pinedo HM, Schluper HMM, Schluper HM, Haisma HJ, and Boven E (1997). Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer. Int J Cancer 71, 237-45.
38. Adams DO, Hall T, Steplewski Z, and Koprowski H (1984). Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive for of antibody-dependent cytolysis. Proc Natl Acad Sci USA 81, 3506-10.
39. Herlyn DM, Steplewski Z, Herlyn MF, and Koprowski H (1980). Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 40, 717-21.
40. Johnson WJ, Steplewski Z, Matthews TJ, Hamilton TA, Koprowski H, and Adams DO (1986). Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation. J Immunol 136, 4704-13.
41. Masucci G, Wersall P, Nielsen J, Nielsen HK, Wigzell H, and Mellstedt H (1989). Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using Mab 17-1A: a combination of potential usefulness in tumor therapy. Hybridoma 8, 507-16.
42. Abdullah N, Greenman J, Pimenidou A, Topping KP, and Monson JR (1999). The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells. Cancer Immunol Immunother 48, 517-24.
43. Cheung N-KV, Walter El, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, and Medof ME (1988). Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 81, 1122-28.
44. Gorter A, Block VT, Haasnoot WHB, Ensink NG, Daha MR, and Fleuren MJ (1996). Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab Invest 74, 1039-49.
45. Waldmann TA, and Strober W (1969). Metabolism of immunoglobulins. Prog Allergy 13, 1-110.
46. Waldmann TA, Strober W, and Blaese RM (1970). Variations in the metabolism of immunoglobulins measured by turnover rates. In Immunoglobulins - biological aspects and uses. E Merler (Ed). National Academy of Sciences, New York, pp. 33-51.
47. Bauer RJ, Gibbons JA, Bell DP, Luo ZP, and Young JD (1994). Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats. J Pharmacol Exp Ther 258, 152-58.
48. Bauer RJ, Dedrick RL, White ML, Murray MJ, and Garovoy MR (1999). Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27, 397-420.
49. Tanswell P, Heinzel G, Greischel A, and Krause J (1990). Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. J Pharmacol Exp Ther 255, 318-24.
50. Palm M, and Mattsson CH (1987). Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin®) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 58, 932-35.
51. Holub M (1989). Immunology of Nude Mice. CRC Press, Boca Raton, FL.